Summer body weight goals are great, but sometimes it’s easy to lose momentum in the colder months. But it’s still possible to make healthy weight loss a priority throughout the winter! Semaglutide and Tirzepatide injections are taking the weight loss market by storm, and they can help support your winter weight loss plan.
These medications are incredibly effective and safe when incorporated into a balanced weight loss plan under the guidance of a skilled medical provider, like Dr. Scott™ at Castle Rock Regenerative Healthcare. We offer Semaglutide and Tirzepatide as part of Dr. Scott’s tailored weight loss programs through in-person or telehealth appointments. Learn how both these treatments can contribute to a slimmer you this winter.
What Are Semaglutide and Tirzepatide?
Tirzepatide and Semaglutide (Ozempic® and Wegovy®) are both FDA-approved weight-loss medications. Delivered as injectables, Semaglutide and Tirzepatide were originally developed to support the management of type 2 diabetes. They have since proven to be effective and safe ways to control appetite and sustainably reduce body weight over time for those without diabetes, too.
How Do Semaglutide and Tirzepatide Work?
Both Semaglutide and Tirzepatide work by delaying gastric emptying and affecting hunger hormones. They are administered as once-weekly injections into the abdominal tissue and are effective in individuals with and without type 2 diabetes, and those with a small or large weight loss goal.
While Semaglutide is a selective GLP-1 (Glucagon-Like Peptide-1) receptor agonist, Tirzepatide is both a GLP-1 and GIP (Glucose-Dependent Insulinotropic Polypeptide) agonist. A GLP-1 agonist controls appetite by mimicking the “I’m full” hormone, while Tirzepatide’s extra GIP factor helps to strengthen this signal and lower LDL cholesterol and triglyceride levels.
How Long After Starting Injections Do I Start Seeing Results?
Each person’s weight loss journey is unique. Many of our clients start to see results in as little as one to two weeks. Also, Semaglutide and Tirzepatide studies show that these therapies are safe to incorporate into any long-term weight loss program.
While Semaglutide and Tirzepatide continue to be effective at managing weight as standalone treatments, we recommend healthy lifestyle changes, as well. These include a healthy diet and exercise routine. Castle Rock Regenerative Healthcare is here to help you meet your regenerative health goals holistically with the guidance of our compassionate team of professionals.
What Kind Of Side Effects Could I Experience?
Some GI-related side effects are tied to Semaglutide and Tirzepatide, but the majority of clients only experience a reduction in appetite. Symptoms may manifest if an individual is experiencing a dosage increase and can include nausea, diarrhea, heartburn, headaches, or constipation.
What Medication Is Best For Me This Winter?
Semaglutide and Tirzepatide are safe and effective solutions for people who want to lose weight or maintain weight loss any time of the year, not just during winter. Dr. Scott™ is a renowned medical professional and trusted provider specializing in advanced regenerative health. He creates unique weight loss plans to meet each individual’s goals year-round.
At CRRH, we offer free consultations with Dr. Scott™! Discuss your health goals and potential weight loss medications that are best for you. Both in-person and telehealth appointments are available here.
Keep your weight loss momentum through the dredges of the colder months with support from Castle Rock Regenerative Healthcare, where we love what we do and help you feel like “you.”
Sources:
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
- Tirzepatide Once Weekly for the Treatment of Obesity
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- Tirzepatide: A Systematic Update
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
- Safety of Semaglutide
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
